Recruiting
A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis
2025-523409-13-00· Phase 1· Lifordi Immunotherapeutics Inc.· Source
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· Phase 3· AstraZeneca· Source
Recruiting
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
2022-502365-26-00· Phase 3· Novartis Pharma AG· Source
Recruiting
A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.
2025-522076-85-00· Phase 2· AstraZeneca AB· Source
Active, not recruiting
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.
2023-503298-39-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source
Recruiting
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
NCT07342478· Phase 3· Newave Pharmaceutical Inc· Source
Recruiting
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
2025-522878-36-00· Phase 3· Celldex Therapeutics Inc.· Source
Active, not recruiting
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· Phase 3· Takeda· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901· Phase 3· Kailera· Source
Active, not recruiting
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
NCT07223697· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875· Phase 3· Kailera· Source
Recruiting
A Study of LAD603 in Adults With Alopecia Areata
NCT07311564· Phase 2· Almirall, S.A.· Source
Active, not recruiting
Study of GS-0151 in Participants With Rheumatoid Arthritis
2024-516520-34-00· Phase 1· Gilead Sciences Inc.· Source
Active, not recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013· Phase 1/2· Eli Lilly and Company· Source
Completed
A Study With CIT-013 in RA Patients
NCT06567470· Phase 2· Citryll BV· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618· Phase 3· Incyte Corporation· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897· Phase 3· AbbVie· Source
Recruiting
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects
with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
2024-511309-47-00· Phase 2· Karyopharm Therapeutics Inc.· Source
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911· Phase 3· Ascentage Pharma Group Inc.· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· Phase 3· AbbVie· Source
Active, not recruiting
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
NCT05785611· Phase 3· Alfasigma S.p.A.· Source
Active, not recruiting
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
NCT05622708· Phase 4· Novartis Pharmaceuticals· Source
Active, not recruiting
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
NCT05222555· Phase 1/2· Incyte Corporation· Source
Active, not recruiting
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116· Phase 3· Sun Pharmaceutical Industries Limited· Source
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377· Phase 1· Enliven Therapeutics· Source
Active, not recruiting
A Study of Rusfertide in Adults With Polycythemia Vera (PV)
NCT05210790· Phase 3· Protagonist Therapeutics, Inc.· Source
Active, not recruiting
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043· Phase 1/2· Heidelberg Pharma AG· Source
Active, not recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· Phase 4· Janssen Research & Development, LLC· Source
Recruiting
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
NCT04638647· Phase 4· Novartis Pharma AG· Source
Active, not recruiting
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308· Phase 3· AbbVie· Source
Active, not recruiting
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032· Phase 3· Merck Sharp & Dohme LLC· Source
Showing 50 of 51.